The inositol (1,4,5)-trisphosphate receptor (InsP 3 R) plays a key role in the intracellular calcium (Ca 2ϩ ) signaling process (1) . InsP 3 R is a tetrameric complex (2, 3) ; each subunit is 2749 amino acids (predicted M.W. is 313 kDa) (reviewed in (4)). InsP 3 R structure consists of three distinct domains: carboxy-terminal Ca 2ϩ channel domain, intermediate coupling domain and amino-terminal ligand-binding domain (4 -6) . The carboxy-terminal region is required for proper InsP 3 R intracellular targeting, oligomerization, and Ca 2ϩ channel formation (7, 8) . The intermediate domain, which mediates a conformational coupling between ligandbinding and Ca 2ϩ channel opening, contains a number of modulatory sites (4) . Amino-terminal ligand-binding domain (InsP 3 R-N) is necessary and sufficient for highaffinity InsP 3 binding (5, 6, 9 -12) .
The InsP 3 R ligand binding site is highly selective for (1,4,5)InsP 3 . Recently two novel InsP 3 R agonists Adenophostins A and B have been discovered in Penicillium brevicompactum cultures (13) (14) (15) . Adenophostin A (AdA) has been chemically synthesized in the laboratory (16 -18) . AdA is the most potent known agonist of InsP 3 R, approximately 10 -15 fold more potent than InsP 3 itself (13-16, 19 -22) . Structurally AdA and InsP 3 are quite diverse, but there are key conserved motifs that are similar (18, 19 
MATERIALS AND METHODS

Expression and Purification of Recombinant InsP 3 R-N-His Protein
GST-InsP 3 R-N-His protein was expressed in 2xYT media for 18 h at room temperature in proteasedeficient BL21 E. coli strain by 0.7 mM IPTG induction (at OD 600 ϭ 0.6). Cells grown in 1 liter culture were cooled on ice, collected by 10 min centrifugation at 5,000 rpm (Beckman JA-10) and resuspended in 50 ml of imidazole lysis buffer (50 mM imidazole pH 6.8, 100 mM NaCl, 10 mM EDTA, 1 mM DTT) with addition of 1 mg/ml lysozyme (Boehringer) and protease inhibitors (1 mg/ml leupeptine, 200 g/ml aprotinin, 1 mM PMSF). Cells were disrupted by repetitive 30 s sonication bursts on ice (Branson Ultrasonics), resulting lysate was cleared by centrifugation at 15,000 rpm for 30 min (Beckman JLA-20 rotor) and concentrated to 10 ml on Amicon YM50 filters under nitrogen pressure. Concentrated lysate was loaded on Sephadex-200 column (Pharmacia) equilibrated in the imidazole lysis buffer. The fractions containing GST-InsP 3 R-N-His protein were collected (60 -110 ml elution volume) by GradiFrac (Pharmacia), pulled together and incubated at the end-over-end shaker with the 1 ml of glutathione beads overnight in the cold room. Glutathione beads were pelleted at 2,500 rpm for 3 min in the microcentrifuge, washed 3 times with the low salt buffer (20 mM imidazole pH 6.8, 100 mM NaCl, 1 mM EDTA, 1 mM DTT), once with high salt buffer (20 mM imidazole pH 6.8, 1 M NaCl, 1 mM EDTA, 1 mM DTT), and once with PBS. Washed beads were resuspended in 5 ml PBS and incubated with 20 units of thrombin for 5-6 h on endover-end shaker in the cold room. After completion of thrombin cleavage the beads were pelleted in the microcentrifuge, the supernatant was collected in the fresh tube, mixed with 0.5 ml of His.Bind beads and incubated in the His binding buffer (20 mM Tris-HCl, pH 7.9, 5 mM imidazole, 0.5 NaCl) for 30 min at endover-end shaker. The His.Bind beads were pelleted by centrifugation, washed with the His binding buffer and the InsP 3 R-N-His protein was eluted from the His.Bind beads in 10 ml of the elution buffer (20 mM Tris-HCl, pH 7.9, 500 mM imidazole, 0.5 NaCl). Obtained sample was dialyzed overnight in the cold room against 2 liters of PBS (14,000 MWCO, Spectrum) and stored at 4°C for prior to binding assays. was generated essentially as described in (27) . Briefly, 0.25 mg (300 nmol) of ShPIP 2 aminoderivative (NH 2 -ShPIP 2 , MW 821) (28) was dissolved in 10 l of 0.1 M sodium-borate buffer (pH 8.5) and reacted with the 0.5 mCi of dried [
125 I]-labeled BoltonHunter reagent (2200 Ci/mmol) for 30 min. The reaction was stopped by addition of 0.5 ml of 0.2 M glycine. Labeled phospholipids were separated from the glycine conjugates and hydrolysis products by gel filtration on Sephadex G-10 (Pharmacia), collected in 0.6 ml fractions and analyzed by ␥-counting. 
Materials
Rat InsP 3 R-I cDNA was a kind gift of Thomas C. Sü dhof (UTSW Medical Center) (29) . Adenophostin A (AdA) was synthesized as described (18) . The syntheses of D-myo-dioctanoyl-(4,5)PIP 2 (ShPIP 2 ) and NH 2 -ShPIP 2 was previously described (28 
RESULTS
The InsP 3 R-N region (M1-F580, MW 62 kDa) of rat InsP 3 R-I cDNA (29) was amplified by PCR and ligated into pGEK-KG vector with the addition of carboxyterminal 6-His-tag to yield pGEX-InsP 3 R-N-His construct (Fig. 1A) . The construct obtained was transformed into protease-deficient BL21 E. coli strain. tion and purified by batch-affinity purification on glutathione beads and His.Bind beads as described in Methods. Final sample and the samples from intermediate stages of purification were separated by SDS-gel electrophoresis and analyzed by Coomassie staining (Fig. 1B) and Western blotting with monoclonal T7.Tag (anti-His tag) antibody (Fig. 1C) . Described procedure typically yielded 0.5-1 mg of at least 95% pure (Fig. 1B, lane 6 (Fig. 3, open squares) . We further demonstrated that AdA binds to InsP 3 R-N with a 10 -15 fold higher affinity than InsP 3 itself (Fig. 3, filled circles) (Fig. 3, open  circles) . The fit to the data (Fig. 3, smooth curve) yielded an IC 50 equal to 11 M ShPIP 2 . Similar results were obtained when stearoyl-arachidonyl-(4,5)PIP 2 vesicles were used in competition experiments instead of ShPIP 2 (data not shown).
PIP 2 can displace InsP 3 from the InsP 3 R ligand binding site (Fig. 3) . Does InsP 3 R-N specifically bind ShPIP 2 ? To answer this question we took advantage of NH 2 -ShPIP 2 derivative (28) . Following the procedure from (27), we generated [ 125 I]ShPIP 2 as described in Methods. The reagent thus generated was utilized in binding experiments with recombinant InsP 3 R-N. ShPIP 2 in micromolar concentrations was able to displace [
125 I]ShPIP 2 from the InsP 3 R-N (Fig. 4 , open circles), supporting a specific InsP 3 R-N association with (Fig. 4, smooth curve) (Fig. 4 , open squares and filled circles), which argues against a simple single-site competition model.
DISCUSSION
We used bacterially expressed and purified to Ͼ95% homogeneity recombinant InsP 3 R ligand-binding domain (InsP 3 R-N) to characterize its binding specificity for InsP 3 In the context of InsP 3 R-PIP 2 functional coupling model we previously proposed specific association of PIP 2 with the InsP 3 R ligand-binding domain (23) , and the data reported here support this hypothesis. The stretch of 15 amino acids is spliced out from the SI site within type I InsP 3 R-N domain (Fig. 1A) in a tissueand developmentally-specific manner (30) . Both SI splice variants display similar InsP 3 binding properties (9) , and the significance of splicing at the SI site for InsP 3 R physiological function is unknown. Here we used SIϪ splice variant of rat type I InsP 3 R-N (29), the predominant isoform in the cerebellum. Notably, 6 out of 15 amino acids in the SI splice insert (VDPDF-EEECLEFQPS) are negatively charged (underlined), and the SIϩ splice isoform of type I InsP 3 R-N may not bind PIP 2 as effectively as SIϪ isoform due to electrostatic repulsion between negatively charged PIP 2 and the cluster of negative charges within SI splice insert. We are in the process of testing this hypothesis experimentally by using methodology outlined in the present paper.
Although ShPIP 2 is able to completely displace InsP 3 from the InsP 3 R-N (Fig. 3) , InsP 3 or AdA cannot completely displace ShPIP 2 (Fig. 4) . These data argue against simple one-site competition model. One possibility is that the InsP 3 -binding site is a part of the PIP 2 -binding site within the InsP 3 R-N sequence. Structural determinants involved in InsP 3 binding to InsP 3 R-N have been extensively characterized by sitedirected mutagenesis (31) and we are taking similar approach to map out determinants responsible for PIP 2 binding. Another related possibility, is that the InsP 3 R-N domain adopts different conformations in InsP 3 -bound and ShPIP 2 -bound states. According to this idea, induced-fit conformational changes in InsP 3 R-N upon ShPIP 2 binding lead to dramatic reduction in affinity for InsP 3 . The fact that in our experiments ShPIP 2 was 10-fold more potent in displacing [
125 I]-ShPIP 2 (Fig. 4, IC (Fig. 3 , IC 50 ϭ 11 M) from InsP 3 R-N may also relate to induced-fit conformational changes in the InsP 3 R-N structure. Different conformations of InsP 3 R ligandbinding domain in InsP 3 -and PIP 2 -occupied states constitute a key element of the InsP 3 R-PIP 2 coupling model (23) , and the availability of sufficient quantities of purified recombinant InsP 3 R-N (Fig. 1, lane 6) should allow us to test this hypothesis by biochemical techniques. Because AdA activate (13-16, 19 -22) and ShPIP 2 inhibit (23) InsP 3 R in functional experiments, we predict that InsP 3 -and AdA-bound conformations of InsP 3 R-N will be similar to each other and different from the ShPIP 2 -bound InsP 3 R-N conformation.
